LONDON – It’s been a busy first week on the job for the new CEO of Santaris Pharma A/S, Donald deBethizy, as a trio of deals was announced, with Roche AG, Glaxosmithkline plc and Isarna Therapeutics GmbH, around the company’s RNA-targeting technology.